SEATTLE–(BUSINESS WIRE)–Cure First, a Seattle-based 501(c)(3) nonprofit expanding access to functional precision medicine for patients with hard-to-treat cancers, today announced plans to more than double its testing capacity over the next year, providing the PARIS Test to more than 240 patients annually, while hiring additional scientific staff to meet rising demand. The expansion comes as oncologists increasingly adopt functional precision medicine amid growing institutional support for the

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.